Thyrocare Technologies Limited, a leading healthcare diagnostics company, has released new insights on India’s fever burden based on testing data collected between 2023 and 2025. The analysis covers over one lakh (108,324) individuals who underwent comprehensive Fever Package testing across PAN India. The findings show that nearly one in three individuals who opted for comprehensive fever testing were diagnosed with a serious infection, including dengue, typhoid, malaria, chikungunya, or leptospirosis.
In India, fever is often brushed off casually. “Just viral." “Wait it out." “Rest and basic medication.” But diagnostic data from 2023 to 2025 tells a far more alarming story, one that turns casual reassurance into a dangerous oversight. Behind what appears to be an ordinary fever, a significant proportion of patients were diagnosed with infections that required medical intervention, from dengue and malaria to typhoid and other illnesses. The numbers challenge a deeply rooted cultural habit – to self-diagnose, self-medicate, and wait.
Typhoid emerged as the most commonly detected infection, identified in nearly one in five patients (18.1 per cent), followed by dengue in about one in seven (14.4 per cent). Malaria, chikungunya and leptospirosis were also recorded across the testing population, further contributing to the overall infectious disease burden.
These findings indicate that a substantial proportion of fever cases are not vague or self-limiting but have clearly identifiable infectious causes. Structured diagnostic testing helps convert clinical uncertainty into timely and targeted medical action.
The data also highlights the presence of multiple infections in a notable proportion of patients. Nearly 10% of infection-positive individuals were diagnosed with co-infections, most commonly a combination of dengue and typhoid. Because these illnesses can present with similar early symptoms but require different treatment approaches, co-infections can complicate diagnosis and delay appropriate care if not identified early.
Rahul Guha, MD & CEO of Thyrocare, said, "Recognising fever as a critical signal empowers patients and clinicians alike to act decisively. It shifts care from reactive treatment to timely and informed intervention. Ultimately, early evaluation, supported by data-driven insights, remains one of the most effective ways to navigate India’s evolving and unpredictable infectious disease landscape.”
Dr Preet Kaur, Chief Scientific Officer, Thyrocare, said, “Data from 2023 to 2025 shows that a significant number of patients carry serious infections, sometimes more than one at a time, revealing patterns that simple assumptions cannot capture. Beyond the visible rise in temperature, laboratory markers highlight hidden stress on organs, from drops in platelet counts to elevated liver enzymes, underscoring that fever is a systemic signal, not an isolated event.”
